RxDoctor Payments Data

Joana Magno, MD

Cardiovascular Disease · Honolulu, HINPI 1447266655

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $20,569 of the $23,008 with a category attached, or 89.4%. It is spread thinly across 34 manufacturers, the largest accounting for just 18.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $5,708 and has fallen 70.2% since, to $1,700 in 2025. Among cardiovascular disease clinicians in HI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$23,008in general payments, 2019–2025

Across 444 payments — averaging $51.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotronik Inc.$4K
  • Abiomed$3K
  • Abbott$2K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$2K
  • Johnson & Johnson$2K
  • Shockwave Medical, Inc$2K
  • plus $9K from 28 others

What the payments were for

  • Travel & lodging$2,41410%
  • Food & beverage$20,56989%
  • Education$250%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,008 in reported general payments places this provider in the 95th percentile of 73 cardiovascular disease providers in Hawaii.

See all cardiovascular disease providers in Hawaii

Medicare billing

Part B allowed, 2024
$78,667
Medicare patients
337
Services billed
885

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban344$403,942
XareltoRivaroxaban156$194,909
EntrestoSacubitril/Valsartan98$149,052
JardianceEmpagliflozin37$48,149
BrilintaTicagrelor39$39,051
Repatha SureclickEvolocumab22$16,321
Atorvastatin Calcium495$12,345
Metoprolol Succinate615$9,695
Rosuvastatin Calcium139$6,794
Ranolazine ErRanolazine26$4,599
ClopidogrelClopidogrel Bisulfate217$4,335
Losartan Potassium282$4,004
Flecainide Acetate49$3,161
Amlodipine Besylate193$2,492
Valsartan57$2,406

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$79$403,942344 claims
Johnson & JohnsonXarelto$1,562$194,909156 claims
NovartisEntresto$434$149,05298 claims
Boehringer IngelheimJardiance$553$48,14937 claims
AstraZenecaBrilinta$927$39,05139 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 73 cardiovascular disease providers in Hawaii.

Other cardiovascular disease in Honolulu

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →